Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?
Identifieur interne : 003447 ( Main/Exploration ); précédent : 003446; suivant : 003448Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?
Auteurs : Daniel Tarsy [États-Unis] ; Ross J. Baldessarini [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-05.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Age Factors, Akathisia, Drug-Induced (epidemiology), Akathisia, Drug-Induced (etiology), Antipsychotic, Antipsychotic Agents (adverse effects), Dyskinesia, Epidemiology, Extrapyramidal syndrome, Humans, Incidence, Nervous system diseases, Neuroleptic, Risk, Risk Factors, Risk factor, Schizophrenia (drug therapy), atypical antipsychotic drugs, atypical neuroleptics, extrapyramidal syndromes, movement disorders, tardive dyskinesia.
- MESH :
- chemical , adverse effects : Antipsychotic Agents.
- drug therapy : Schizophrenia.
- epidemiology : Akathisia, Drug-Induced.
- etiology : Akathisia, Drug-Induced.
- Age Factors, Humans, Incidence, Risk, Risk Factors.
Abstract
Second‐generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long‐term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modern APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies of patients never treated with traditional neuroleptics and exposed to only a single modern APD are required to quantify TD risks with specific drugs. Long‐term use of APDs should continue to be based on research‐supported indications, with regular specific examination for emerging TD. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20823
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000450
- to stream Istex, to step Curation: 000450
- to stream Istex, to step Checkpoint: 001F07
- to stream PubMed, to step Corpus: 002D42
- to stream PubMed, to step Curation: 002D42
- to stream PubMed, to step Checkpoint: 002D38
- to stream Ncbi, to step Merge: 001589
- to stream Ncbi, to step Curation: 001589
- to stream Ncbi, to step Checkpoint: 001589
- to stream Main, to step Merge: 004761
- to stream PascalFrancis, to step Corpus: 001B61
- to stream PascalFrancis, to step Curation: 001160
- to stream PascalFrancis, to step Checkpoint: 001B08
- to stream Main, to step Merge: 004C03
- to stream Main, to step Curation: 003447
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?</title><author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name></author><author><name sortKey="Baldessarini, Ross J" sort="Baldessarini, Ross J" uniqKey="Baldessarini R" first="Ross J." last="Baldessarini">Ross J. Baldessarini</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:34A6B749D9546BB2AF065F893AF882A8305E9086</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20823</idno><idno type="url">https://api.istex.fr/document/34A6B749D9546BB2AF065F893AF882A8305E9086/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000450</idno><idno type="wicri:Area/Istex/Curation">000450</idno><idno type="wicri:Area/Istex/Checkpoint">001F07</idno><idno type="wicri:doubleKey">0885-3185:2006:Tarsy D:epidemiology:of:tardive</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16532448</idno><idno type="wicri:Area/PubMed/Corpus">002D42</idno><idno type="wicri:Area/PubMed/Curation">002D42</idno><idno type="wicri:Area/PubMed/Checkpoint">002D38</idno><idno type="wicri:Area/Ncbi/Merge">001589</idno><idno type="wicri:Area/Ncbi/Curation">001589</idno><idno type="wicri:Area/Ncbi/Checkpoint">001589</idno><idno type="wicri:doubleKey">0885-3185:2006:Tarsy D:epidemiology:of:tardive</idno><idno type="wicri:Area/Main/Merge">004761</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:06-0289023</idno><idno type="wicri:Area/PascalFrancis/Corpus">001B61</idno><idno type="wicri:Area/PascalFrancis/Curation">001160</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001B08</idno><idno type="wicri:doubleKey">0885-3185:2006:Tarsy D:epidemiology:of:tardive</idno><idno type="wicri:Area/Main/Merge">004C03</idno><idno type="wicri:Area/Main/Curation">003447</idno><idno type="wicri:Area/Main/Exploration">003447</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?</title><author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Harvard Medical School, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, Beth Israel‐Deaconess Medical Center, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Baldessarini, Ross J" sort="Baldessarini, Ross J" uniqKey="Baldessarini R" first="Ross J." last="Baldessarini">Ross J. Baldessarini</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry, Harvard Medical School, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Psychopharmacology Program, McLean Division of Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-05">2006-05</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="589">589</biblScope><biblScope unit="page" to="598">598</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">34A6B749D9546BB2AF065F893AF882A8305E9086</idno><idno type="DOI">10.1002/mds.20823</idno><idno type="ArticleID">MDS20823</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term><term>Akathisia, Drug-Induced (epidemiology)</term><term>Akathisia, Drug-Induced (etiology)</term><term>Antipsychotic</term><term>Antipsychotic Agents (adverse effects)</term><term>Dyskinesia</term><term>Epidemiology</term><term>Extrapyramidal syndrome</term><term>Humans</term><term>Incidence</term><term>Nervous system diseases</term><term>Neuroleptic</term><term>Risk</term><term>Risk Factors</term><term>Risk factor</term><term>Schizophrenia (drug therapy)</term><term>atypical antipsychotic drugs</term><term>atypical neuroleptics</term><term>extrapyramidal syndromes</term><term>movement disorders</term><term>tardive dyskinesia</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Schizophrenia</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Akathisia, Drug-Induced</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Akathisia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>Humans</term><term>Incidence</term><term>Risk</term><term>Risk Factors</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antipsychotique</term><term>Dyskinésie</term><term>Epidémiologie</term><term>Extrapyramidal syndrome</term><term>Facteur risque</term><term>Neuroleptique</term><term>Système nerveux pathologie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Second‐generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long‐term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modern APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies of patients never treated with traditional neuroleptics and exposed to only a single modern APD are required to quantify TD risks with specific drugs. Long‐term use of APDs should continue to be based on research‐supported indications, with regular specific examination for emerging TD. © 2006 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Massachusetts</li></region></list><tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name></region><name sortKey="Baldessarini, Ross J" sort="Baldessarini, Ross J" uniqKey="Baldessarini R" first="Ross J." last="Baldessarini">Ross J. Baldessarini</name><name sortKey="Baldessarini, Ross J" sort="Baldessarini, Ross J" uniqKey="Baldessarini R" first="Ross J." last="Baldessarini">Ross J. Baldessarini</name><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003447 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003447 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:34A6B749D9546BB2AF065F893AF882A8305E9086
|texte= Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?
}}
| This area was generated with Dilib version V0.6.23. |  |